Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02734615 · ClinicalTrials.gov registry record · Phase 1
Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 199
- Enrollment target
NCT02734615 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 199 participants.
The verdict
NCT02734615, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 199 participants
- Enrollment target
Study Summary
To characterize the safety and tolerability, identify recommended doses and regimens for future studies, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LSZ102 as a single agent and in combination with either LEE011 or BYL719 in adult patients with locally advanced or metastatic ER+ breast cancer who have progressed after endocrine therapy.
Interventions
- DRUG LEE011
- DRUG BYL719
- DRUG LSZ102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2016-06-14 |
| Est. Completion | 2021-09-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02734615
The ClinicalTrials.gov registry entry for NCT02734615 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which LEE011 is the first listed.
NCT02734615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02734615 about?
NCT02734615 is a clinical study titled "Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers". To characterize the safety and tolerability, identify recommended doses and regimens for future studies, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LSZ102 as a single agent and in combination with either LEE011 or BYL719 in adult patients with locally advanced or metasta...
What is the current status of trial NCT02734615?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 199 participants. The study started on 2016-06-14. Estimated completion is 2021-09-13.
What interventions are being tested in trial NCT02734615?
The interventions under investigation include: LEE011 (DRUG), BYL719 (DRUG), LSZ102 (DRUG).
Who is sponsoring clinical trial NCT02734615?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.